NeuBase Therapeutics Inc. (NBSE)

Business: NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes.

IPO Date: 01-May-2007

Founder, Pres, CEO & Chairman: Dr. Dietrich A. Stephan Ph.D.

Chief Operating Officer: Dr. William Roland Mann MBA, Ph.D.

Listing: NASDAQ: NBSE

Country: United States

Headquarters: Pittsburgh, PA

Website: https://www.neubasetherapeutics.com

Market cap: $28.39 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-33.47 Mln

Cash: $38.96 Mln

Total Debt: $6.32 Mln

Insider's Holding: 8.69%

Liquidity: Low

52 Week range: $0.77 - 4.91

Shares outstanding: 32,258,700

10 Years Aggregate:

• CFO: $-97.70 Mln
• EBITDA: $-156.59 Mln
• Net Profit: $-164.00 Mln